There was an error in the original publication [1]. The conflict of interest statement was incomplete as the authors forgot to include this statement.
The updated statement is as follows:
Conflicts of Interest: Jerome Boissier is the cofounder of ParaDev company that was subcontracted to carry out the antiparasitic tests on the Schistosome.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Embo-Ibouanga, A.W.; Nguyen, M.; Joly, J.-P.; Coustets, M.; Augereau, J.-M.; Paloque, L.; Vanthuyne, N.; Bikanga, R.; Robert, A.; Benoit-Vical, F.; et al. Peptide-Alkoxyamine Drugs: An Innovative Approach to Fight Schistosomiasis: “Digging Their Graves with Their Forks”. Pathogens 2024, 13, 482. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).